SCHOTT Pharma AG & Co. KGaA: SCHOTT Pharma publishes preliminary Q3 key figures and raises 2026 revenue and earnings guidance
Veröffentlicht: 08.07.2026 um 18:45 Uhr, dgap.de| EQS-Ad-hoc: SCHOTT Pharma AG & Co. KGaA / Key word(s): Forecast / Full year/Results / Quarter SCHOTT Pharma AG & Co. KGaA: SCHOTT Pharma publishes preliminary Q3 key figures and raises 2026 revenue and earnings guidance 08-Jul-2026 / 18:45 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this announcement. Based on preliminary figures for the third quarter of 2026, SCHOTT Pharma expects constant-currency revenue growth of approximately 8% and an EBITDA margin of approximately 27%. Current market expectations are for constant-currency revenue growth of 3.5% and an EBITDA margin of 27.5% (Source: Vara Consensus, July 6, 2026). For fiscal year 2026, SCHOTT Pharma now expects constant-currency revenue growth of 5% to 6% (previously: 2% to 5%) and an EBITDA margin of 27% to 28% (previously: around 27%). Both figures are above current market expectations of 3.2% for constant-currency revenue growth and 27.2% for the EBITDA margin (Source: Vara Consensus, July 6, 2026). The raised guidance is supported by the company’s strong business performance and expectations for the fourth quarter of 2026, as well as an agreement reached with a key customer for glass syringes. This agreement includes both revenue-related and compensation components, which will have an impact on future periods. SCHOTT Pharma will publish its Q3 2026 quarterly statement on August 12, 2026. Notifying person: Tobias Erfurth Head of Investor Relations SCHOTT Pharma AG & Co. KGaA Hattenbergstr. 10, 55122 Mainz, Germany phone: +49 (0)6131 661640 Tobias.Erfurth@schott.com www.schott-pharma.com End of Inside Information 08-Jul-2026 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. View original content: EQS News |
| Language: | English |
| Company: | SCHOTT Pharma AG & Co. KGaA |
| Hattenbergstraße 10 | |
| 55122 Mainz | |
| Germany | |
| Phone: | +49 6131660 |
| E-mail: | ir.pharma@schott.com |
| Internet: | https://ir.schott-pharma.com/ |
| ISIN: | DE000A3ENQ51 |
| WKN: | A3ENQ5 |
| Indices: | SDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate BSX |
| EQS News ID: | 2362904 |
| End of Announcement | EQS News Service |
| |
2362904 08-Jul-2026 CET/CEST
en | DE000A3ENQ51 | SCHOTT PHARMA AG & CO. KGAA | boerse | 69725401 |
